ReviewMultidisciplinary respiratory medicine2019
Immunostimulants in respiratory diseases: focus on Pidotimod.
Review in Multidisciplinary respiratory medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 38 citations in OpenAlex.
- Reducing HPV Viral Burden in Men: A Synergistic Approach Using Pidotimod and Prophylactic Vaccination.Microorganisms · 2026Article
- Immunostimulant-induced maturation of monocyte-derived dendritic cells in respiratory infection prophylaxis.Drugs in context · 2026Article
- Effects of Neutrophil-Activating Protein ofAdvanced biomedical research · 2025Article
- Pidotimod in pediatrics: new evidence and future perspectives.Multidisciplinary respiratory medicine · 2024Article
- Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants.Computational and structural biotechnology journal · 2022Review
- Parameters of nonspecific resistance of calves with respiratory pathology before and after treatment.Journal of advanced veterinary and animal research · 2021Article
- Mushroom-Derived Bioactive Molecules as Immunotherapeutic Agents: A Review.Molecules (Basel, Switzerland) · 2021Review
- The Protective Effects of Helicobacter pylori Infection on Allergic Asthma.International archives of allergy and immunology · 2021Review
- Prevention of New Respiratory Episodes in Children with Recurrent Respiratory Infections: An Expert Consensus Statement.Microorganisms · 2020Review
- Enhancing innate immunity against virus in times of COVID-19: Trying to untangle facts from fictions.The World Allergy Organization journal · 2020Review
- Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients.Mediterranean journal of hematology and infectious diseases · 2020Article
- A Model for SARS-CoV-2 Infection with Treatment.Computational and mathematical methods in medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Usefulness of Pidotimod and its role as immunostimulant, has been discussed, we know, for several decades. Nevertheless, there is still much to know. Understanding its mechanisms and its potential usefulness in airway infections and its prevention, asthma both Th2 and non Th2 type, bronchiectasis, as adjuvant in vaccination and in allergen immunotherapy still remains to clearly unveil. The aim of this paper was to provide a useful updated review of the role of the main available immunostimulants, giving particular focus on Pidotimod use and its potentials utility in respiratory diseases. Pidotimod showed its usefulness in reducing need for antibiotics in airway infections, increasing the level of immunoglobulins (IgA, IgM, IgG) and T-lymphocyte subsets (CD3+, CD4+) endowed with immunomodulatory activity that affect both innate and adaptive immune responses. Higher expression of TLR2 and of HLA-DR molecules, induction of dendritic cell maturation and release of pro-inflammatory molecules, stimulation of T lymphocyte proliferation and differentiation toward a Th1 phenotype, as well as an increase of the phagocytosis have been demonstrated to be associated with Pidotimod in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.